Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katarzyna Skierka"'
Autor:
Patrycja Wińska, Łukasz Widło, Elżbieta Senkara, Mirosława Koronkiewicz, Jarosław M. Cieśla, Alicja Krzyśko, Katarzyna Skierka, Joanna Cieśla
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Thymidylate synthase (TS), dihydrofolate reductase (DHFR), and serine hydroxymethyltransferase (SHMT) constitute the thymidylate synthesis cycle providing thymidylate for DNA synthesis and repair. Our previous studies indicated that TS and DHFR are t
Externí odkaz:
https://doaj.org/article/7996ee4219e6416abfab7151045eb4d9
Autor:
Mirosława Koronkiewicz, Alicja Krzyśko, Maria Bretner, Jarosław M. Cieśla, Patrycja Wińska, Joanna Cieśla, Katarzyna Skierka, Łukasz Widło
Publikováno v:
Anticancer Research. 39:3531-3542
Background/aim Recently, we demonstrated the ability of inhibitors of protein kinase 2 (casein kinase II; CK2) to enhance the efficacy of 5-fluorouracil, a thymidylate synthase (TYMS)-directed drug for anticancer treatment. The present study aimed to
Autor:
Elżbieta Senkara, Dominik Cysewski, Paweł Wilamowski, Joanna Cieśla, Monika Wielechowska, Maria Bretner, Patrycja Wińska, Katarzyna Skierka
Publikováno v:
Biochemical and Biophysical Research Communications. 513:368-373
Dihydrofolate reductase (DHFR) is a prominent molecular target in antitumor, antibacterial, antiprotozoan, and immunosuppressive chemotherapies, and CK2 protein kinase is an ubiquitous enzyme involved in many processes, such as tRNA and rRNA synthesi
Autor:
Patrycja Wińska, Katarzyna Skierka, Joanna Cieśla, Edyta Łukowska-Chojnacka, Maria Bretner, Mirosława Koronkiewicz
Publikováno v:
Anticancer Research. 38:4617-4627
Background/aim Protein kinase CK2 was recently identified as a promising therapeutic target for combination therapy. Our study aims to investigate the anticancer effect of a simultaneous inhibition of thymidylate synthase (TS) and CK2 in MCF-7 breast
Publikováno v:
Bioorganic chemistry. 72
Protein kinase 2 (CK2), a member of the serine/threonine kinase family, has been established as a promising target in anticancer therapy. New derivatives of known CK2 inhibitors 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi) and 4,5,6,7-tetrabromo-1H-ben